The molecular brakes and accelerators of the immune system. Learn how checkpoint interactions determine immunotherapy response and why measuring engagement beats measuring expression.
Immune checkpoint inhibitors have changed the landscape of oncology. For some patients with metastatic melanoma—once facing a prognosis of months—these therapies have brought durable remissions that were previously unimaginable. But the reality remains sobering: only a fraction of patients respond, and we still cannot reliably predict who will benefit. For patients and families navigating these decisions, the uncertainty is profound.
The standard approach measures checkpoint protein expression—how much PD-L1 is on the tumor surface. But expression doesn't tell you whether PD-1 and PD-L1 are actually engaged. A tumor can express high PD-L1 without it binding PD-1. A patient with low PD-L1 expression might still have active checkpoint engagement in the right microenvironment.
This learning path will take you through the checkpoint landscape: from the basic concept of immune regulation, through the major therapeutic targets, to the emerging checkpoints that may define the next generation of immunotherapy.
Before diving into specific checkpoints, understand why they exist. The immune system is extraordinarily powerful—capable of destroying any cell in the body. Checkpoints evolved to prevent this power from being turned against healthy tissue. Cancer exploits these same mechanisms to evade destruction.
PD-1/PD-L1 is the most clinically important checkpoint axis. Pembrolizumab, nivolumab, atezolizumab—the blockbuster immunotherapy drugs all target this interaction. When PD-1 on a T cell binds PD-L1 on a tumor cell, it tells the T cell to stand down. Blocking this interaction unleashes the immune response. But here's the key insight: measuring whether this interaction is actually happening predicts response far better than measuring whether the proteins are present.
CTLA-4 was the first checkpoint targeted therapeutically. Ipilimumab's approval in 2011 proved that releasing immune brakes could produce durable cancer remissions. But CTLA-4 operates differently from PD-1: it acts earlier in T cell activation, in lymph nodes rather than tumors. Understanding this distinction matters for combination strategies and patient selection.
With PD-1 and CTLA-4 established, the field has turned to additional checkpoints. LAG-3 received FDA approval in 2022 (in combination with PD-1 blockade), validating the multi-checkpoint approach. Like PD-1, LAG-3 suppresses T cell function in the tumor microenvironment—but through distinct mechanisms that may be additive or synergistic with existing therapies.
TIGIT represents the cutting edge of checkpoint biology—and also its challenges. Multiple phase 3 trials have produced mixed results, highlighting that not every checkpoint is equally druggable and that patient selection may be critical. The TIGIT story underscores why functional measurement matters: we need to identify patients where the checkpoint is actually engaged before expecting benefit from blocking it.
You now understand the checkpoint landscape and why engagement matters more than expression. The next step is seeing the clinical evidence—studies where measuring checkpoint interaction has helped identify patients most likely to benefit from immunotherapy, offering hope for more informed treatment decisions.
Continue to Clinical Applications
